Mesane Tümörlerinde Radyolojik Değerlendirme

Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: Costs and considerations of caring for this disease. Eur Urol. 2014;66:253–262.

National Collaborating Center for Cancer. Bladder Cancer: Diagnosis and Management. London: National Institute for Health and Care Excellence(UK); February 2015.

Sherif A, Garske U, Torre M, et al. Hybrid SPECT-CT: An Additional Technique for Sentinel Node Detection of Patients with Invasive Bladder Cancer. Eur Urol. 2006;50:83–91.

Witjes JA, Comperat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–792.

Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.

Sobin LH, Gospodarowicz MK, Wittekind C, International Union Against Cancer (UICC). TNM classification of malignant tumours. John Wiley & Sons; 2011

Sungmin W, Cho JY. Bladder Cancer: Imaging. In: Bladder Cancer. Academic Press. 2018;87-122.

Galgano SJ, Porter KK, Burgan C, et al. The Role of Imaging in Bladder Cancer Diagnosis and Staging. Diagnostics (Basel). 2020;10:703.

Gupta VG, Kumar S, Singh SK, et al. Contrast enhanced ultrasound in urothelial carcinoma of urinary bladder: An underutilized staging and grading modality. Cent Eur J Urol. 2016;69:360–365.

Arslan H, Tezcan FM, Alğın O. Urothelial cancers: clinical and imaging evaluation. Turk J Med Sci. 2012;42:1335-1364

Tritschler S, Mosler C, Tilki D, et al. Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology. 2012;79:131721

Kawashima A, Vrtiska TJ, LeRoy AJ, et al. CT urography. Radiographics. 2004;24:S35–S58.

Salmanoglu E, Halpern E, Trabulsi EJ, et al. A glance at imaging bladder cancer. Clin Transl Imaging. 2018;6:257-269.

Vikram R, Sandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. Am J Roentgenol. 2009;192:14817.

Pecoraro M, Takeuchi M, Vargas HA, et al. Overview of VI‐RADS in bladder cancer. Am J Roentgenol. 2020;214: 1259‐ 1268.

Hafeez S, Huddart R. Advances in bladder cancer imaging. BMC Med. 2013;11:104.

Soubra A, Hayward D, Dahm P. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol. 2016;34(9):1229–1237.

Chakraborty D, Mittal BR, Kashyap R, et al. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Diagnostic Evaluation of Carcinoma Urinary Bladder: Comparison with Computed Tomography. World J Nucl Med. 2014;13:34–39.

Sharma A, Mete UK, Sood A, et al. Utility of early dynamic and delayed post-diuretic 18F-FDG PET/CT SUV max in predicting tumour grade and T-stage of urinary bladder carcinoma: results from a prospective single centre study. BJR. 2017;90:20160787

Xue M, Liu L, Du G, et al Diagnostic Evaluation of 18F-FDG PET/CT Imaging in Recurrent or Residual Urinary Bladder Cancer: A Meta-Analysis. Urol J. 2020;16.

Rosenkrantz AB, Friedman KP, Ponzo F, et al. Prospective pilot study to evaluate the incremental value of PET information in patients with bladder cancer undergoing 18F-FDG simultaneous PET/MRI. Clin Nucl Med. 2017;42:e8–e15

Tekes A, Kamel IR, Chan TY, et al. MR imaging features of non-transitional cell carcinoma of the urinary bladder with pathologic correlation. Am J Roentgenol. 2003;180:77984.

Thali-Schwab CM, Woodward PJ, Wagner BJ. Computed tomographic appearance of urachal adenocarcinomas: review of 25 cases. Eur Radiol. 2005;15:7984.